LY288513 

LY288513 is a selective non-peptide CCK-B receptor antagonist with an IC₅₀ value of 16 nM. LY288513 produces an anxiolytic-like action in mice^[1][2][3].

IC50: 16 nM (CCK-B receptor)^[1]

LY288513 (10 nM; 2 days) suppresses the effects of CCK-8 on CD4⁺ T cell subset-specific transcription factors^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

LY288513 (3, 10 mg/kg, i.p.; 10, 30 mg/kg, p.o.) produces an anxiolytic-like action in mice^[3].
LY288513 (1000 mg/kg, p.o.) potentiates the effects of a CNS depressant, slightly lowered body temperature, and had modest sedative effects only at the highest dose examined^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

436.30

C₂₂H₁₈BrN₃O₂

147523-65-7

O=C(N1NC([C@@H](C2=CC=CC=C2)[C@@H]1C3=CC=CC=C3)=O)NC4=CC=C(Br)C=C4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Rasmussen K. CCK, schizophrenia, and anxiety. CCK-B antagonists inhibit the activity of brain dopamine neurons. Ann N Y Acad Sci. 1994 Mar 23;713:300-11.  [Content Brief]

  [2]. Zhang JG, et al. Cholecystokinin octapeptide regulates the differentiation and effector cytokine production of CD4(+) T cells in vitro. Int Immunopharmacol. 2014;20(2):307-315.  [Content Brief]

  [3]. Helton DR, et al. Central nervous system characterization of the new cholecystokininB antagonist LY288513. Pharmacol Biochem Behav. 1996 Mar;53(3):493-502.  [Content Brief]